Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastrap Direct
- Development stage
- Unknown
- Lead developer
- Biokuris
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
Gastrap Direct is an orally administered, fixed-combination gastrointestinal medical-nutrition and Class IIa medical-device product developed from KitoZyme-derived chitin-glucan and simethicone. BK001 is intended for symptomatic management of gas-related gastrointestinal disorders, including bloating, flatulence, abdominal pain, and disturbed intestinal transit; it has been studied in irritable bowel syndrome. Simethicone provides a local antifoaming effect that facilitates gas elimination, while the chitin-glucan component is intended to improve stool characteristics and support restoration of a balanced intestinal microbiota. A prospective open-label multicenter study of the product in IBS reported improvements in abdominal pain, bloating, abdominal distension, and stool consistency. ([biokuris.com](https://biokuris.com/our-first-clinical-paper-on-our-lead-product-bk001/))
- Brand names
- Gastrap DirectNovacalm
- Other names
- chitin-glucan + simethicone
Beyond the preview
Go deeper on Gastrap Direct.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gastrap Direct.